Cybin Inc. to Host November 13 Conference Call for Q2 2025 Financial Results and Business Update

Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) will host a conference call and webcast at 8 a.m. ET Thursday, November 13, 2025, to provide a business update and report financial results for its second quarter ended September 30, 2025. The company, which operates as a late-stage breakthrough neuropsychiatry company, is committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

With promising class-leading data, Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients. The company's current development pipeline includes CYB003, a proprietary deuterated psilocin analog in Phase 3 studies for the adjunctive treatment of major depressive disorder. This investigational treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, highlighting its potential to address significant medical needs.

Additionally, Cybin is developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule currently in a Phase 2 study for generalized anxiety disorder. The company also maintains a research pipeline of investigational, 5-HT-receptor focused compounds, expanding its potential impact on neuropsychiatric treatment. Founded in 2019, Cybin maintains operational presence in Canada, the United States, the United Kingdom and Ireland, positioning it as a global player in the emerging psychedelic medicine sector.

The upcoming conference call represents a significant opportunity for investors and stakeholders to gain insight into Cybin's financial performance and clinical progress. The timing coincides with critical development milestones for both CYB003 and CYB004, making the business update particularly important for understanding the company's trajectory in the competitive neuropsychiatry space. Additional company information and updates are available through the company's newsroom at https://ibn.fm/CYBN.

This announcement follows Cybin's ongoing commitment to transparency and investor communication as it advances its novel treatment candidates through clinical development. The conference call will provide detailed financial results for the quarter ended September 30, 2025, along with updates on clinical trial progress, regulatory developments, and corporate strategy. The webcast format ensures broad accessibility for interested parties globally, reflecting the international nature of Cybin's operations and investor base.